Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes

Core Insights - Biomea Fusion, Inc. has completed enrollment for the first three dose expansion arms of the COVALENT-111 study, with over 260 type 2 diabetes patients participating [1][4] Group 1: Study Overview - COVALENT-111 is a multi-site, randomized, double-blind, placebo-controlled Phase I/II clinical trial focusing on type 2 diabetes patients who are uncontrolled by standard care [2][5] - The Phase II portion includes multiple dose escalation and expansion cohorts, evaluating the drug BMF-219 over varying durations and dosages [2][5] Group 2: Drug Details - BMF-219 is being evaluated for its ability to provide durable glycemic control, with early results showing promising outcomes after just 4 weeks of treatment [4] - The expansion phase aims to investigate the effects of longer dosing regimens of BMF-219, specifically over 8 to 12 weeks [4] Group 3: Company Background - Biomea Fusion is focused on developing oral covalent small molecules to treat metabolic diseases and genetically defined cancers, offering potential advantages over conventional drugs [6][7] - The company utilizes its proprietary FUSION™ System to design and develop next-generation medicines aimed at maximizing clinical benefits for patients [7]